ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of “Moderate Buy” from Analysts

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has been given an average recommendation of “Moderate Buy” by the seven research firms that are presently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $4.14.

ALXO has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $5.00 price objective on shares of ALX Oncology in a report on Friday, March 7th. Stifel Nicolaus cut their price target on shares of ALX Oncology from $3.00 to $1.50 and set a “hold” rating on the stock in a research report on Friday, March 7th. Jefferies Financial Group upgraded shares of ALX Oncology from a “hold” rating to a “buy” rating and boosted their price objective for the company from $2.00 to $3.00 in a report on Thursday, March 6th. Piper Sandler boosted their price target on shares of ALX Oncology from $8.00 to $9.00 and gave the company an “overweight” rating in a report on Thursday, March 6th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research note on Friday, January 24th.

Hedge Funds Weigh In On ALX Oncology

Large investors have recently added to or reduced their stakes in the company. Two Sigma Investments LP boosted its position in shares of ALX Oncology by 6.7% during the fourth quarter. Two Sigma Investments LP now owns 704,131 shares of the company’s stock worth $1,176,000 after buying an additional 44,072 shares during the period. Two Sigma Advisers LP boosted its position in ALX Oncology by 64.6% during the 4th quarter. Two Sigma Advisers LP now owns 823,900 shares of the company’s stock worth $1,376,000 after acquiring an additional 323,400 shares during the last quarter. Nuveen Asset Management LLC grew its stake in shares of ALX Oncology by 55.6% during the 4th quarter. Nuveen Asset Management LLC now owns 164,790 shares of the company’s stock worth $275,000 after acquiring an additional 58,896 shares in the last quarter. Deutsche Bank AG raised its holdings in shares of ALX Oncology by 521.0% in the fourth quarter. Deutsche Bank AG now owns 101,113 shares of the company’s stock valued at $169,000 after purchasing an additional 84,830 shares during the last quarter. Finally, Bridgeway Capital Management LLC bought a new stake in shares of ALX Oncology in the fourth quarter worth $125,000. Institutional investors own 97.97% of the company’s stock.

ALX Oncology Stock Performance

Shares of ALX Oncology stock opened at $0.51 on Wednesday. The firm has a fifty day moving average of $0.94 and a two-hundred day moving average of $1.37. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.82 and a current ratio of 4.82. The stock has a market capitalization of $27.00 million, a price-to-earnings ratio of -0.17 and a beta of 1.20. ALX Oncology has a 52 week low of $0.48 and a 52 week high of $17.83.

About ALX Oncology

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.